BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31981306)

  • 1. In silico identification and characterization of antineoplastic asparaginase enzyme from endophytic bacteria.
    Zadeh Hosseingholi E; Neghabi N; Molavi G; Gheibi Hayat SM; Shahriarpour H
    IUBMB Life; 2020 May; 72(5):991-1000. PubMed ID: 31981306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rhizobium etli asparaginase II: an alternative for acute lymphoblastic leukemia (ALL) treatment.
    Huerta-Saquero A; Evangelista-Martínez Z; Moreno-Enriquez A; Perez-Rueda E
    Bioengineered; 2013; 4(1):30-6. PubMed ID: 22895060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Structural In Silico Analysis of the Immunogenicity of L-Asparaginase from
    Andrade KCR; Homem-de-Mello M; Motta JA; Borges MG; de Abreu JAC; de Souza PM; Pessoa A; Pappas GJ; de Oliveira Magalhães P
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A structural in silico analysis of the immunogenicity of l-asparaginase from Escherichia coli and Erwinia carotovora.
    Belén LH; Lissabet JB; de Oliveira Rangel-Yagui C; Effer B; Monteiro G; Pessoa A; Farías Avendaño JG
    Biologicals; 2019 May; 59():47-55. PubMed ID: 30871932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erwinia chrysanthemi L-asparaginase: epitope mapping and production of antigenically modified enzymes.
    Moola ZB; Scawen MD; Atkinson T; Nicholls DJ
    Biochem J; 1994 Sep; 302 ( Pt 3)(Pt 3):921-7. PubMed ID: 7945221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and Characterization of Erwinia Chrysanthemi l-Asparaginase Variants with Diminished l-Glutaminase Activity.
    Nguyen HA; Su Y; Lavie A
    J Biol Chem; 2016 Aug; 291(34):17664-76. PubMed ID: 27354283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Back to the future: the amazing journey of the therapeutic anti-leukemia enzyme asparaginase
    Tong WH; Rizzari C
    Haematologica; 2023 Oct; 108(10):2606-2615. PubMed ID: 37470157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-Asparaginase from Erwinia Chrysanthemi 3937: cloning, expression and characterization.
    Kotzia GA; Labrou NE
    J Biotechnol; 2007 Jan; 127(4):657-69. PubMed ID: 16984804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteins from Erwinia asparaginase Erwinase ® and E. coli asparaginase 2 MEDAC ® for treatment of human leukemia, show a multitude of modifications for which the consequences are completely unclear.
    Bae N; Pollak A; Lubec G
    Electrophoresis; 2011 Jul; 32(14):1824-8. PubMed ID: 21769889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A potential type-II L-asparaginase from marine isolate Bacillus australimaris NJB19: Statistical optimization, in silico analysis and structural modeling.
    Chakravarty N; Priyanka ; Singh J; Singh RP
    Int J Biol Macromol; 2021 Mar; 174():527-539. PubMed ID: 33508362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacterial l-asparaginases for cancer therapy: Current knowledge and future perspectives.
    Ghasemian A; Al-Marzoqi AH; Al-Abodi HR; Alghanimi YK; Kadhum SA; Shokouhi Mostafavi SK; Fattahi A
    J Cell Physiol; 2019 Nov; 234(11):19271-19279. PubMed ID: 30993718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreasing the immunogenicity of Erwinia chrysanthemi asparaginase via protein engineering: computational approach.
    Yari M; Eslami M; Ghoshoon MB; Nezafat N; Ghasemi Y
    Mol Biol Rep; 2019 Oct; 46(5):4751-4761. PubMed ID: 31290058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microbial L-asparaginase as a promising enzyme for treatment of various cancers.
    Darvishi F; Jahanafrooz Z; Mokhtarzadeh A
    Appl Microbiol Biotechnol; 2022 Sep; 106(17):5335-5347. PubMed ID: 35871694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A critical review on properties and applications of microbial l-asparaginases.
    Krishnapura PR; Belur PD; Subramanya S
    Crit Rev Microbiol; 2016 Sep; 42(5):720-37. PubMed ID: 25865363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Silico Design of a Chimeric Humanized L-asparaginase.
    Pedroso A; Herrera Belén L; Beltrán JF; Castillo RL; Pessoa A; Pedroso E; Farías JG
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of subvisible particulates in lyophilised Erwinia chrysanthemi L-asparaginase and relationship with clinical experience.
    Gervais D; Corn T; Downer A; Smith S; Jennings A
    AAPS J; 2014 Jul; 16(4):784-90. PubMed ID: 24854894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circumventing the side effects of L-asparaginase.
    Fonseca MHG; Fiúza TDS; Morais SB; Souza TACB; Trevizani R
    Biomed Pharmacother; 2021 Jul; 139():111616. PubMed ID: 33932739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural Aspects of
    Maggi M; Scotti C
    Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative immunogenicity and structural analysis of epitopes of different bacterial L-asparaginases.
    Pokrovsky VS; Kazanov MD; Dyakov IN; Pokrovskaya MV; Aleksandrova SS
    BMC Cancer; 2016 Feb; 16():89. PubMed ID: 26867931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endophytic Fungi as a Promising Source of Anticancer L-Asparaginase: A Review.
    Parashiva J; Nuthan BR; Rakshith D; Satish S
    Curr Microbiol; 2023 Jul; 80(9):282. PubMed ID: 37450223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.